Synexus’ Pretoria clinical research center has enrolled more patients than any other site across the world in a type 2 diabetes trial for Janssen Pharmaceuticals.

Janssen, a pharmaceutical company of Johnson & Johnson, established more than 99 sites across the globe to enroll the more than 716 patients needed for the study. Synexus, which is the largest multi-national company entirely focused on the recruitment and running of clinical trials at its own dedicated research centers, exceeded its recruitment target by more than 50% at its Watermeyer site in Pretoria.

Synexus country manager Dr. Sanet Aspinall commented, “We are often able to exceed our pharma and CRO client’s expectations as we have a very effective enrollment team to recruit patients from the large pool of people surrounding our research centers. This team has developed a sophisticated outreach program which works closely with GPs, primary care clinics and public hospitals in order to find the right patients quickly.”

Linda Roach, the GCO country manager of Janssen Pharmaceuticals in South Africa said, “Within our regulatory environment here in South Africa, we need to partner with sites that can enroll quickly with quality data and can support our efforts to achieve our recruitment targets. Synexus Watermeyer site in Pretoria is one such site."

"This is of particularly importance in South Africa as regulatory timelines can be slow leaving a shorter time frame in which to find these patients. Selection of the right site and infrastructure for this study has proven that, the country can not only deliver but exceed the target number of patients,” Roach continued.